Omidenepag

Ophthalmic
Ocular hypertension, Open-angle glaucoma

Aphakia or pseudophakia. Concomitant use with tafluprost.

Patient with active ocular inflammation (e.g. iritis, uveitis), angle-closure glaucoma. Pregnancy and lactation.

Significant: Increased pigmentation of the iris and eyelid skin, eyelash changes (e.g. increased length, thickness, and number of lashes), ocular inflammation, macular oedema (including cystoid macular oedema).
Eye disorders: Conjunctival hyperaemia, photophobia, blurred vision, dry eye, eye pain or irritation, ocular hyperaemia, punctate keratitis, visual impairment, corneal thickening, corneal epithelial disorders.
General disorders and administration site conditions: Instillation site pain.
Nervous system disorders: Headache.

This drug may cause temporary blurred vision or photophobia, if affected, do not drive or operate machinery. If you are using more than 1 topical eye medicine, administer them at least 5 minutes apart. Remove contact lenses prior to application and reinsert 15 minutes after administration.

Monitor IOP. Regularly examine patients who develop increased iris pigmentation.

Increased risk of moderate to severe photophobia and ocular inflammation (e.g. iritis) with tafluprost. Increased frequency of ocular inflammatory adverse reactions (e.g. conjunctival hyperaemia) with timolol.

Description:
Mechanism of Action: Omidenepag is a relatively selective prostaglandin E2 (EP2) receptor agonist which decreases IOP. The exact mechanism of its IOP-lowering effect is currently unknown; however, it is considered to increase aqueous outflow via both trabecular and uveoscleral outflow pathways by stimulating EP2 receptors.
Pharmacokinetics:
Absorption: Omidenepag isopropyl (prodrug) is absorbed through the cornea. Time to peak plasma concentration: 10-15 minutes.
Metabolism: Omidenepag isopropyl is rapidly metabolised in the eye to omidenepag via hydrolysis by carboxylesterase-1; omidenepag is further metabolised in the liver via oxidation, N-dealkylation, glucuronidation, and sulfate or taurine conjugation.

Source: National Center for Biotechnology Information. PubChem Compound Summary for CID 44230575, Omidenepag. https://pubchem.ncbi.nlm.nih.gov/compound/Omidenepag. Accessed Mar. 29, 2023.

Unopened bottle: Store between 2-8°C. Once opened, it can be stored up to 30°C and use within 1 month. Protect from light.

Antiglaucoma Preparations

S01EX06 - omidenepag ; Belongs to the class of other antiglaucoma preparations.

Anon. Omidenepag Isopropyl. AHFS Clinical Drug Information [online]. Bethesda, MD. American Society of Health-System Pharmacists, Inc. https://www.ahfscdi.com. Accessed 26/01/2023.

Anon. Omidenepag Isopropyl. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 27/01/2023.

Eybelis Ophthalmic Solution 0.002% (Santen Pharma Malaysia Sdn. Bhd.). MIMS Malaysia. http://www.mims.com/malaysia. Accessed 26/01/2023.

Eybelis Ophthalmic Solution 0.002% (Santen Pharma Malaysia Sdn. Bhd.). National Pharmaceutical Regulatory Agency - Ministry of Health Malaysia. https://www.npra.gov.my. Accessed 26/01/2023.

Eybelis Ophthalmic Solution 0.002% (Santen Pharmaceutical Co., Ltd.). MIMS Singapore. http://www.mims.com/singapore. Accessed 26/01/2023.

Omlonti Ophthalmic Solution 0.002% (Santen Incorporated). U.S. FDA. https://www.fda.gov. Accessed 26/01/2023.

Omlonti Solution/Drops (Santen Incorporated). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 26/01/2023.